<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0">
<channel>
<title>Annals of Clinical Hypertension</title>
<link>https://www.theskygallerypattaya.com/hjch</link>
<description>A Heighpubs Open Access Journal</description>
<language>en-us</language>
	<item>
		<title>Incidence of hypertension in a high-risk workgroup (Police officers) - Observational study</title>
		<pubDate>11/08/2019</pubDate>
		<link>https://www.theskygallerypattaya.com/hjch/ach-aid1020.php</link>
		<description>&amp;lt;h2&amp;gt;Summary&amp;lt;/h2&amp;gt;

&amp;lt;p&amp;gt;&amp;lt;strong&amp;gt;Introduction:&amp;lt;/strong&amp;gt; Hypertension is a silent pathology in a way that affects all four spheres to be considered as such; magnitude, transcendence vulnerability, and feasibility. The World Health Organization estimates that 45% of deaths from heart disease and 51% of deaths from stroke globally are caused by hypertension.&amp;lt;br /&amp;gt;
&amp;lt;strong&amp;gt;Material and method:&amp;lt;/strong&amp;gt; A longitudinal, descriptive and quantitative observational study was carried out on the personnel of high-risk public service providers.&amp;lt;br /&amp;gt;
&amp;lt;strong&amp;gt;Results:&amp;lt;/strong&amp;gt; The total population sampled was 550 people where it was possible to determine the sex where the disease predominates, since 92% of the hypertensive population belong to the male sex, while 8% of the female population. 57% of the total population were classified as normotensive, while 21% were classified as High Normal, Grade I Hypertension, and Grade II Hypertension.&amp;lt;br /&amp;gt;
&amp;lt;strong&amp;gt;Discussion:&amp;lt;/strong&amp;gt; AHT is the result of a series of interactions between endogenous and exogenous factors in an organism that tries to adapt to the increase of the cardiac output and the peripheral resistance of the blood vessels, which is manifested by the increase in blood pressure figures. Physical activity has been shown to have a lower risk of hypertension compared to sedentary individuals. The daily stress these workers face predisposes them to suffer their manifestations as headache, muscle pain, fatigue, digestive disorders and constant elevations of blood pressure.&amp;lt;/p&amp;gt;</description>
	</item>
	<item>
		<title>Compliance of hypertensive patients with antihypertensive drug therapy at the Renaissance Hospital of Nâ€™Djamena, Chad</title>
		<pubDate>10/23/2019</pubDate>
		<link>https://www.theskygallerypattaya.com/hjch/ach-aid1019.php</link>
		<description>&amp;lt;h2&amp;gt;Abstract&amp;lt;/h2&amp;gt;

&amp;lt;p&amp;gt;&amp;lt;strong&amp;gt;Introduction:&amp;lt;/strong&amp;gt; High blood pressure is a major cardiovascular risk factor. In hypertension, non-compliance is frequent. The objective of this work is to evaluate the therapeutic observances and to identify the predictive factors of poor compliances in Chadian hypertensive patients.&amp;lt;/p&amp;gt;

&amp;lt;p&amp;gt;&amp;lt;strong&amp;gt;Patients and Methods:&amp;lt;/strong&amp;gt; It was a prospective cross-sectional study over a six-month period from January 15 to July 15, 2019. This was performed in the outpatient Cardiology and Nephrology units at the Renaissance Hospital of N&amp;amp;rsquo;Djamena. We included all follow-up patients who had hypertension who consulted during the study period. However, dialysis patients and children were excluded from this study. The parameters studied were demographic characteristics, economic and therapeutic data and the rate of therapeutic compliance.&amp;lt;/p&amp;gt;

&amp;lt;p&amp;gt;&amp;lt;strong&amp;gt;Results:&amp;lt;/strong&amp;gt; Eighty-seven patients were included. The average age was 50 years old. The sex ratio was 2.5. Sixty-seven percent (n = 58) of the patients were from urban areas. The predominant cardiovascular risk factors were smoking in 25% (n = 22) and diabetes in 23% (n = 20). Hypertension was uncontrolled in 76% (n = 66) patients. Adherence was poor in 66% (n = 57) of patients. The monthly cost of treatment was respectively 10,000 and 20,000 FCFA in 52% (n = 45) of cases. Combination therapy was observed in 70% of cases (n = 61) and 56% (n = 49) of patients had more than one drug intake. The adherence rate was 93% (n = 28) in the urban population (&amp;lt;em&amp;gt;p&amp;lt;/em&amp;gt; &amp;amp;lt; 0.001). All patients (n = 30) who were observing their treatment were educated (p &amp;amp;lt; 0.001). The adherence rate was 20% (n = 6) in patients who had a monthly income less than 100,000 FCFA (&amp;lt;em&amp;gt;p&amp;lt;/em&amp;gt; = 0.004). The adherence rate was 60% (n = 18) when the monthly cost was less than FCFA 10,000 (&amp;lt;em&amp;gt;p&amp;lt;/em&amp;gt; = 0.003). The adherence rate was 77% (n = 23) in patients receiving monotherapy (&amp;lt;em&amp;gt;p&amp;lt;/em&amp;gt; &amp;amp;lt; 0.001).&amp;lt;/p&amp;gt;

&amp;lt;p&amp;gt;&amp;lt;strong&amp;gt;Conclusion:&amp;lt;/strong&amp;gt; This study showed a low level of adherence in Chadian hypertensive patients. The complexity and cost of antihypertensive therapy, poor knowledge of hypertension, and ignorance of its severity have been the main factors of poor compliance.&amp;lt;/p&amp;gt;</description>
	</item>
	<item>
		<title>Validation of the Omron HBP-9031C blood pressure monitor for clinics and hospitals according to the ANSI/AAMI/ISO 81060-2:2013 protocol</title>
		<pubDate>08/13/2019</pubDate>
		<link>https://www.theskygallerypattaya.com/hjch/ach-aid1018.php</link>
		<description>&amp;lt;h2&amp;gt;Abstract&amp;lt;/h2&amp;gt;

&amp;lt;p&amp;gt;&amp;lt;strong&amp;gt;Objective: &amp;lt;/strong&amp;gt;The present study aimed to evaluate the accuracy of the Omron HBP-9031C automated oscillometric upper-arm blood pressure (BP) measurement device for blood pressure monitoring, according to the ANSI/AAMI/ISO 81060-2:2013 protocol (ANSI/AAMI/ISO).&amp;lt;/p&amp;gt;

&amp;lt;p&amp;gt;&amp;lt;strong&amp;gt;Participants and Method: &amp;lt;/strong&amp;gt;The device evaluations were performed in 85 participants, who fulfilled the inclusion criteria of the protocol. The validation procedure and data analysis followed the protocol precisely.&amp;lt;/p&amp;gt;

&amp;lt;p&amp;gt;&amp;lt;strong&amp;gt;Results: &amp;lt;/strong&amp;gt;In the ANSI/AAMI/ISO 81060-2-2013 validation procedure (criterion 1), the mean &amp;amp;plusmn; SD of the differences between the test device and reference BP was 0.5 &amp;amp;plusmn; 7.84/-1.9 &amp;amp;plusmn; 6.30 mmHg (systolic/diastolic). The mean differences between the two observers and the Omron HBP-9031C were 0.5 &amp;amp;plusmn; 6.69 mmHg (range, &amp;amp;minus;18 to 15 mmHg) for systolic BP and -1.9 &amp;amp;plusmn; 5.63 mmHg (range, &amp;amp;minus;17 to 14 mmHg) for diastolic BP, according to criterion 2. The two criteria of the ANSI/AAMI/ISO were fulfilled.&amp;lt;/p&amp;gt;

&amp;lt;p&amp;gt;&amp;lt;strong&amp;gt;Conclusion: &amp;lt;/strong&amp;gt;The professional OMRON BP monitor, HBP-9031C fulfilled the requirements of the ANSI/AAMI/ISO validation standard and can be recommended for clinical use.&amp;lt;/p&amp;gt;</description>
	</item>
	<item>
		<title>The New (2018) European Hypertension Guidelines an overview and comments</title>
		<pubDate>07/24/2019</pubDate>
		<link>https://www.theskygallerypattaya.com/hjch/ach-aid1017.php</link>
		<description>&amp;lt;h2&amp;gt;Review Article&amp;lt;/h2&amp;gt;

&amp;lt;p&amp;gt;The European Society of Cardiology (ESC) and the European Society of Hypertension (ESH) jointly developed a series of hypertension guidelines in the years 2003, 207 and 2013. The most recent guidelines were issued by the two societies in August this year (2018) and were published in the European Heart Journal. The new guidelines are printed in more than 90 pages and cover almost all aspects of hypertension based on extensive review of literature giving highest priority to data from randomized controlled trials and well conducted meta-analysis. In important areas where there is inadequate or no evidence, guidelines authors resort to expert opinion. The text was developed over approximately 24 months and was reviewed by representatives of ESC and ESH national hypertension societies. Although it is less than five years since the last hypertension European guidelines in 2013, the recent 2018 guidelines show important differences in diagnosis and treatment strategies with the addition of new sections and recommendations on management of hypertensive emergencies, hypertension in women and pregnancy, different ethnic groups, chronic obstructive pulmonary disease, cancer therapies, peri-operative management, sexual dysfunction and perioperative management.&amp;lt;/p&amp;gt;

&amp;lt;p&amp;gt;In this message, I will give an overview of the main recommendations in the European guidelines under two headings: diagnosis and treatment and I will conclude by comments.&amp;lt;/p&amp;gt;

&amp;lt;p&amp;gt;The European Society of Cardiology (ESC) and the European Society of Hypertension (ESH) jointly developed a series of hypertension guidelines in the years 2003, 207 and 2013. The most recent guidelines were issued by the two societies in August this year (2018) and were published in the European Heart Journal. The new guidelines are printed in more than 90 pages and cover almost all aspects of hypertension based on extensive review of literature giving highest priority to data from randomized controlled trials and well conducted meta-analysis. In important areas where there is inadequate or no evidence, guidelines authors resort to expert opinion. The text was developed over approximately 24 months and was reviewed by representatives of ESC and ESH national hypertension societies. Although it is less than five years since the last hypertension European guidelines in 2013, the recent 2018 guidelines show important differences in diagnosis and treatment strategies with the addition of new sections and recommendations on management of hypertensive emergencies, hypertension in women and pregnancy, different ethnic groups, chronic obstructive pulmonary disease, cancer therapies, peri-operative management, sexual dysfunction and perioperative management.&amp;lt;br /&amp;gt;
In this message, I will give an overview of the main recommendations in the European guidelines under two headings: diagnosis and treatment and I will conclude by comments.&amp;lt;/p&amp;gt;</description>
	</item>
	<item>
		<title>Circulating platelet-derived vesicle in atrial fibrillation</title>
		<pubDate>06/27/2019</pubDate>
		<link>https://www.theskygallerypattaya.com/hjch/ach-aid1016.php</link>
		<description>&amp;lt;h2&amp;gt;Abstract&amp;lt;/h2&amp;gt;

&amp;lt;p&amp;gt;Platelet vesiculation is common factor contributing in coagulation and thromboembolism in patients with atrial fibrillation (AF). Platelet-derived vesicles are involved in the coagulation, thromboembolism, microvascular inflammation, arterial stiffness, vascular calcification, atherosclerotic plaque shaping and rupture, endothelial dysfunction, cardiac remodelling, and kidney dysfunction. Recent clinical studies have revealed elevated concentrations of platelet-derived vesicles in peripheral blood of patients with current AF and history of AF. The aim of the mini review is to discuss the role of platelet-derived micro vesicles as predictive biomarker in AF. Serial measures of circulating levels of platelet-derived vesicules are discussed to be useful in stratification of AF patients at risk of thromboembolic complications, but there is limiting evidence regarding their predictive value that requires further investigations in large clinical trials.&amp;lt;/p&amp;gt;</description>
	</item>
	<item>
		<title>Hypertension as a persistent public health problem. A position paper from Alliance for a Healthy Heart, Mexico</title>
		<pubDate>04/03/2019</pubDate>
		<link>https://www.theskygallerypattaya.com/hjch/ach-aid1015.php</link>
		<description>&amp;lt;h2&amp;gt;Summary&amp;lt;/h2&amp;gt;

&amp;lt;p&amp;gt;Today, Mexico has more than 130 million inhabitants; 85 millions of them are adults of 20 or more years old. The population pyramid is still one of base wider and this base corresponds to adults younger than 54 years old. Despite predictions made 20 years ago, about a transformation of the population pyramid shape to a mushroom shape as a consequence of more life expected and adult population growth; this change has not been occurred. Hypertension has become the biggest challenge of noncommunicable chronic diseases to public health in Mexico. Around 30% of adult Mexican population has hypertension; 75% of them have less than 54 years old (in productive age); 40% of them are unaware but only 50% of aware hypertensive population takes drugs and, 50% of them are controlled (&amp;amp;lt; 140/90 mmHg). Cardiovascular risk factors including hypertension, dyslipidemia, obesity, and diabetes often cohabit in the same person and are magnified one to another in terms of common pathophysiological pathways. Atherosclerosis, arrhythmias, stroke and heart failure are common and are the final pathologic end-points and explains why cardiovascular diseases occupy first place in mortality in Mexico and worldwide. The costs of care for these diseases are billionaires and if we do not generate appropriate strategies, their global impact can become a high threat to social development of the country. The life style like nutrition, sports habits of the Mexicans must be emphasized; there is poor education about this crucial topic. This position paper is focused on the principal controversies and strategies to be developed by all, government, society, physicians, nurses, patients and all people related with healthcare of hypertension, in order to confront this huge public health problem in Mexico.&amp;lt;/p&amp;gt;</description>
	</item>
	<item>
		<title>Heart Failure with preserved Ejection Fraction (HFpEF); A Mexican cohort from Mexican Institute of Social Security (IMSS)</title>
		<pubDate>01/28/2019</pubDate>
		<link>https://www.theskygallerypattaya.com/hjch/ach-aid1014.php</link>
		<description>&amp;lt;h2&amp;gt;Abstract&amp;lt;/h2&amp;gt;

&amp;lt;p&amp;gt;&amp;lt;strong&amp;gt;Background: &amp;lt;/strong&amp;gt;Several epidemiologic studies indicate that up to 50% of patients with heart failure have a preserved ejection fraction, and this proportion has increased over time. The knowledge of its severity and associated comorbidity is determining factor to develop adequate strategies for its treatment and prevention. This study was focus on the creation of a cohort and follow-up of Mexican population and to analyze its severity as well as its interaction with the comorbidity of other cardiovascular risk factors.&amp;lt;/p&amp;gt;

&amp;lt;p&amp;gt;&amp;lt;strong&amp;gt;Methods: &amp;lt;/strong&amp;gt;We included patients from different sites of Mexico City than were sent to the Cardiology hospital of the National Medical Center in Mexico City for the realization of an echocardiogram as part of their assessment by the presence of dyspnea, edema, or suspicion of hypertensive heart disease. Complete medical history, physical examination and laboratory studies including Brain Natriuretic Peptide (BNP) serum levels were performed. Diagnosis of diastolic dysfunction was based on symptoms and echocardiographic data including time of deceleration, size of left atrium, e&amp;amp;acute; septal and e&amp;amp;acute; lateral, as well as E wave, A wave and its ratio E/A. All patients had left ventricle ejection fraction &amp;amp;gt; 45%.&amp;lt;/p&amp;gt;

&amp;lt;p&amp;gt;&amp;lt;strong&amp;gt;Results: &amp;lt;/strong&amp;gt;We included 168 patients with HFpEF. The most common risk factor was hypertension (89.2%), followed by overweight and obesity (&amp;amp;gt; 78.5%), dyslipidemia (82.1%) and diabetes (42.8%). Women were dominant, 108 (64.3%); the mean age was 63 years old. When we classify by severity of diastolic dysfunction, we found that 41.1% were grade I, 57.1% were grade II and only 1.8% were grade III. The risk factors most strongly associated with the severity of diastolic dysfunction were hypertension, obesity and dyslipidemia. We found BNP levels highly variables, but the levels were higher detected as the ejection fraction was approaching to 45%. At one year of follow up mortality was not reported.&amp;lt;/p&amp;gt;

&amp;lt;p&amp;gt;&amp;lt;strong&amp;gt;Conclusion: &amp;lt;/strong&amp;gt;HFpEF is a frequent entity in patients with cardiovascular risk factors in Mexico. The most common risk factor was hypertension. The combination of hypertension, overweight and dyslipidemia predicted the severity of diastolic dysfunction. We recommend that all Mexican patient with hypertension and overweight or obesity should be submitted as a part of its medical evaluation to an echocardiogram study in order to detect diastolic dysfunction even though the signs or symptoms are or not evident.&amp;lt;/p&amp;gt;</description>
	</item>
	<item>
		<title>Strategic Plans for Diagnosis, Treatment and Control of Hypertension</title>
		<pubDate>11/23/2018</pubDate>
		<link>https://www.theskygallerypattaya.com/hjch/ach-aid1013.php</link>
		<description>&amp;lt;h2&amp;gt;Abstract&amp;lt;/h2&amp;gt;

&amp;lt;p&amp;gt;Two major challenges face the practicing physicians and medical community regarding the management of hypertension. First is accurate diagnosis and finding who is the truly hypertensive patient in need of life-long treatment. Second is to improve blood pressure control through addressing hypertension risk factors, adherence to treatment and frequent monitoring.&amp;lt;br /&amp;gt;
- Current Challenges in Management&amp;lt;/p&amp;gt;

&amp;lt;ul&amp;gt;
	&amp;lt;li&amp;gt;Accurate diagnosis of hypertension&amp;lt;/li&amp;gt;
	&amp;lt;li&amp;gt;Improving blood pressure control&amp;lt;/li&amp;gt;
&amp;lt;/ul&amp;gt;

&amp;lt;p&amp;gt;- What Do We Need For The Future?&amp;lt;/p&amp;gt;</description>
	</item>
	<item>
		<title>What is the Cost of Measuring a Blood Pressure?</title>
		<pubDate>10/11/2018</pubDate>
		<link>https://www.theskygallerypattaya.com/hjch/ach-aid1012.php</link>
		<description>&amp;lt;h2&amp;gt;Abstract&amp;lt;/h2&amp;gt;

&amp;lt;p&amp;gt;&amp;lt;strong&amp;gt;Rationale:&amp;lt;/strong&amp;gt; Blood Pressure measurement has transitioned to the oscillometric method in most hospitals in the United States, however out-patient offices mainly use the auscultatory technique.&amp;lt;/p&amp;gt;

&amp;lt;p&amp;gt;&amp;lt;strong&amp;gt;Objective: &amp;lt;/strong&amp;gt;To determine time taken to measure blood pressure by an automatic oscillometric device compared to an auscultatory measurement device and to determine what each measurement costs.&amp;lt;/p&amp;gt;

&amp;lt;p&amp;gt;&amp;lt;strong&amp;gt;Methods: &amp;lt;/strong&amp;gt;Blood Pressures were measured in a single primary care office by medical assistants (MA) for patients seen for office visits. Timed measurements were performed using an automated oscillometric Welch Allyn Connex Vital Signs Monitor (WA) and manually using a Tycos device. A minimum of 400 readings were taken with each method.&amp;lt;/p&amp;gt;

&amp;lt;p&amp;gt;&amp;lt;strong&amp;gt;Results:&amp;lt;/strong&amp;gt; The average time to manually measure BP was 58.6 seconds, whereas the WA average was 39.8 seconds, 18.8 seconds faster (p&amp;amp;lt;0.05). There was an improvement in measurement time with MA experience with the WA device (p&amp;amp;lt;0.05). The average MA cost to measure a single BP using the manual method was $0.35 vs. the WA method ($0.24) or a savings of $0.11 per measurement. The improvement with experience of WA method reduced cost to $0.17 per measurement.&amp;lt;/p&amp;gt;

&amp;lt;p&amp;gt;&amp;lt;strong&amp;gt;Conclusion:&amp;lt;/strong&amp;gt; The oscillometric method saved 17cents per measurement potentially saving $1,119 per year for our primary care practice.&amp;lt;/p&amp;gt;</description>
	</item>
	<item>
		<title>Role of the Kidneys in the Regulation of Intra-and Extra-Renal Blood Pressure</title>
		<pubDate>07/17/2018</pubDate>
		<link>https://www.theskygallerypattaya.com/hjch/ach-aid1011.php</link>
		<description>&amp;lt;h2&amp;gt;Abstract&amp;lt;/h2&amp;gt;

&amp;lt;p&amp;gt;Hypertension is one of the most common chronic diseases of human, affecting more than one billion people worldwide. When it becomes chronic, hypertension leaves behind cardiac hypertrophy, heart failure, stroke, and kidney disease, resulting in substantial morbidity and mortality. Treatments that effectively reduce blood pressure can prevent these complications. Abnormalities in the production of urine by the kidneys have been implicated in increased vascular resistance, leading to high blood pressure and increased cardiac mass. By matching urinary excretion of salt and water with dietary intake, balance is usually attained, thereby maintaining a constant extracellular fluid volume and blood pressure. Based on the capacity for the kidney to excrete sodium, this blood pressure-altering mechanism should have sufficient advantage to limit intravascular volume and consequently lower blood pressure in response to a range of stimuli from elevated heart rate to increase peripheral vascular resistance. A major determinant of the level of intra- and extra- renal blood pressure is therefore sodium handling, and it is controlled by complex physiological mechanism by hormones, inflammatory mediators, and the sympathetic nervous system. Homoeostasis and favourable influence sodium balance are a basic mechanism of efficacy for diuretics and dietary sodium restriction in hypertension. Renin Angiotensin System (RAS) inhibitors, vasodilators, and &amp;amp;beta;-blockers work to facilitate pressure-natriuresis. Also, WNK signaling pathways, soluble inflammatory mediators, and pathways regulating extra-renal sodium disposition may be the focus towards elimination of sodium and reducing blood pressure in hypertension.&amp;lt;/p&amp;gt;</description>
	</item>
	<item>
		<title>Cardiovascular risk reduction: Past, present and future in Mexico</title>
		<pubDate>07/17/2018</pubDate>
		<link>https://www.theskygallerypattaya.com/hjch/ach-aid1010.php</link>
		<description>&amp;lt;h2&amp;gt;Summary&amp;lt;/h2&amp;gt;

&amp;lt;p&amp;gt;Atherosclerotic cardiovascular disease (ASCVD) is globally defined as coronary heart disease, cerebrovascular disease, or peripheral arterial disease presumed to be of atherosclerotic origin and it is the leading cause of morbidity and mortality for individuals with or without diabetes and is the largest contributor to the direct and indirect catastrophic costs of cardiovascular disorder. Very common conditions coexisting into the cardiovascular risk (e.g., obesity, hypertension, diabetes and dyslipidemia) are clear risk factors for ASCVD, and diabetes itself confers independent risk. Numerous studies have shown the efficacy of controlling individual cardiovascular risk factors in preventing or slowing ASCVD in people with these disorders. In other words it is not enough control one risk factor. We need to develop novel strategies to detect and control all of them at the same time. Thus, large benefits are seen when multiple cardiovascular risk factors are addressed&amp;amp;nbsp;simultaneously. Under the current paradigm of aggressive risk factor modification in patients with cardiovascular risk, there is evidence that measures of 10-year coronary heart disease (CHD) risk among U.S. adults with cardiovascular risk have improved significantly over the past decade and that ASCVD morbidity and mortality have decreased. In Mexico the Mexican Institute of Social Security is implementing new strategies of primary and secondary prevention in order to confront this pandemic.&amp;lt;/p&amp;gt;

&amp;lt;p&amp;gt;In this review, we analyze the state of the art to approach at the same time the different cardiovascular risk factors, in an integral form because of this is the real worldwide challenge of health.&amp;lt;/p&amp;gt;</description>
	</item>
	<item>
		<title>Guidelines that are just for guidance</title>
		<pubDate>04/09/2018</pubDate>
		<link>https://www.theskygallerypattaya.com/hjch/ach-aid1009.php</link>
		<description>&amp;lt;h2&amp;gt;Review&amp;lt;/h2&amp;gt;

&amp;lt;p&amp;gt;Hypertension (HTN) is a widely prevalent disease across the globe. Recent reports from National Health and Nutrition Examination Surveys (NHANES) indicate that the prevalence of HTN is 29% in adults more than 18 years in the US [1]. This is about 72 million adults. Worldwide, about 1.3 billion people are affected by HTN [2]. This number is projected to increase several-fold in the coming years. Given the huge burden of this disease to the healthcare system and the many deleterious effects that can result from uncontrolled HTN, we need strong guidelines to manage the same. The recently published 2017 ACC/AHA guidelines [3] on hypertension management are very meticulous and include a comprehensive stepwise approach in treating hypertension. Here we present a summary of the major changes and a concise review of the new guidelines.&amp;lt;/p&amp;gt;</description>
	</item>
	<item>
		<title>What is new in Hypertension of Mexico 2018? -Impact of the new classifi cation of high blood pressure in adults from American College of Cardiology/American Heart Association (ACC/AHA)</title>
		<pubDate>03/07/2018</pubDate>
		<link>https://www.theskygallerypattaya.com/hjch/ach-aid1008.php</link>
		<description>&amp;lt;h2&amp;gt;Abstract&amp;lt;/h2&amp;gt;

&amp;lt;p&amp;gt;The new report of American College of Cardiology/American Heart Association task force on Clinical Practice Guidelines for High Blood Pressure in Adults was published online ahead of print November 13, 2017. The new American recommendation was focused on the criteria to define Hypertension. 130/80 mmHg or more is now considered as the new cut off point to define Hypertension. It is not new if we consider cumulative evidence in the las two decades has been broken the idea to consider 140/90 mmHg as the point to start medical actions. Thus, in M&amp;amp;eacute;xico with current ACC/AHA definition it is estimated today around 48 million of adult hypertensive population. In the Mexican Institute of Social Security (IMSS) several strategies has been developed to improve prevention as the key action to confront non communicable chronic disease including hypertension. This updated guideline from ACC/AHA is an extraordinary opportunity to reinforce our preventive programs to high blood pressure control. In this brief report we analyze the epidemiological situation in Mexico and its possible consequences of the new criteria for hypertension diagnosis. The main current strategies that are applied into the IMSS to confront cardiovascular risk factors are directed to prevention. The IMSS is prepared to attend situations as the change of criteria diagnoses in Hypertension and new preventive models are in progression.&amp;lt;/p&amp;gt;</description>
	</item>
	<item>
		<title>Role of Home Blood Pressure Monitoring in Overcoming Therapeutic Inertia and Improving Hypertension Control in Mexico</title>
		<pubDate>02/19/2018</pubDate>
		<link>https://www.theskygallerypattaya.com/hjch/ach-aid1007.php</link>
		<description>&amp;lt;h2&amp;gt;Summary&amp;lt;/h2&amp;gt;

&amp;lt;p&amp;gt;Hypertension remains the most common modifiable cardiovascular risk factor, however, control of hypertension rates remain dismal. Home blood pressure (BP) monitoring has the potential to improve the control of hypertension. Home BP monitoring is now defended evenly for the evaluation and management of hypertension. This paper shows the experience of the National Association of Mexican Cardiologist in a group of patients with hypertension under drug treatment to evaluate the control in a real world clinical practice in Mexico. One hundred and fifty one patients were included. They were followed during two weeks with three home measurements at day (8:00, 14:00 and 20:00hr). An Ambulatory blood pressure of 24hr was performed at the middle of study. At the end of the study 36% (54/151) patients still uncontrolled by systolic blood pressure (&amp;amp;gt;135 mmHg) and 31% by diastolic blood pressure similar results were detected by ambulatory blood pressure. During afternoon and night uncontrolled values were more common. Home blood pressure monitoring, results in a better form to detect uncontrolled patients and help clinical judgment to adjust pharmacological therapy. This practice should be recommended in Mexico.&amp;lt;/p&amp;gt;</description>
	</item>
	<item>
		<title>Treating Blood Hypertension in a Brazilian Community: Moving from Reactive Homeostatic Model to Proactive Allostatic Healthcare</title>
		<pubDate>01/26/2018</pubDate>
		<link>https://www.theskygallerypattaya.com/hjch/ach-aid1006.php</link>
		<description>&amp;lt;h2&amp;gt;Abstract&amp;lt;/h2&amp;gt;

&amp;lt;p&amp;gt;The responsiveness of hypertensive subjects to different types of physical exercises and length of intervention, has been investigated in samples of our dynamic cohort study (&amp;amp;ldquo;Move for Health&amp;amp;rdquo; program) based on spontaneous demand for healthy lifestyle with supervised exercises and dietary counseling. After clinical selection and baseline assessments they were spontaneously assigned to exercise protocols of strength (PAc) isolated or combined with endurance (walking) exercises (PMi) daily or in alternated days(PMiA), hydrogymnastics(PHy) and tread mill high- intensity exercises(PHit), applied during 10(experiment 1) and 20(experiment 2) weeks of intervention. Baseline demographic, socioeconomic, anthropometric and physical activity and fitness characteristics were similar among protocols. Ten-week training improved VO2max. Similarly in all protocols while hand grip increased only in PAc. In average, there was a 16% reduction rate of hypertension rate from baseline with both, SBP and DBP, reduced by PHy and only SBP by the PMi. After adjustments hypertension was more reduced by PAc, PMi and PHy. In the 20-week experiment, higher SBP was similarly reduced by PAc or PMiA and DBP by PMiA, after adjustments. Hence, so far, our generated data suggest physical exercises as an effective tool for hypertension reduction, from 10 weeks to 3 year-long supervised protocols composed by surface or aquatic activities with strength or endurance exercises. PAc takes longer and short-period responsiveness can be achieved by either combined (strength-endurance) or hydrogymnastic exercises. Thus, exercise training is a time-and type-dependent tool, feasible, costless and scientific-based rheostatic-allostatic alternative for the current &amp;amp;ldquo;sick-care&amp;amp;rdquo; drug-dependent homeostatic approach to hypertension med care.&amp;lt;/p&amp;gt;</description>
	</item>
	<item>
		<title>Does serum uric acid play a protective role against tissue damage in cardiovascular and metabolic diseases?</title>
		<pubDate>07/18/2017</pubDate>
		<link>https://www.theskygallerypattaya.com/hjch/ach-aid1005.php</link>
		<description>&amp;lt;h2&amp;gt;Abstract&amp;lt;/h2&amp;gt;

&amp;lt;p&amp;gt;Previous clinical, observation and epidemiologic studies have demonstrated strong association between serum uric acid (SUA) and cardiovascular disease (hypertension, heart failure, and asymptomatic atherosclerosis), metabolic states (abdominal obesity, diabetes mellitus, metabolic syndrome, insulin resistance) and kidney disease. There is a large body of evidence regarding the role of SUA as predictor of CV events and CV mortality in general population and individuals with established CV disease and metabolic diseases. However, SUA may exhibit protective effects on endothelium and vasculature as well as attenuate endogenous repair system through mobbing and differentiation of cell precursors. Although SUA lowering drugs are widely used in patients with symptomatic hyperuricemia and gout beyond their etiologies, there is no agreement of SUA below target level 6.0 mg/dL in asymptomatic individuals with kidney injury and CV disease and data of ones are sufficiently limited. The short communication is depicted on the controversial role of SUA as primary cell toxicity agent and secondary cell protector against hypoxia, ischemia and apoptosis.&amp;lt;/p&amp;gt;</description>
	</item>
	<item>
		<title>Systolic Blood Pressure Determinants</title>
		<pubDate>07/11/2017</pubDate>
		<link>https://www.theskygallerypattaya.com/hjch/ach-aid1004.php</link>
		<description>&amp;lt;h2&amp;gt;Abstract&amp;lt;/h2&amp;gt;

&amp;lt;p&amp;gt;Hypertension and blood pressure are closely related, and hypertension is directly related with stroke. There are different type of blood pressures such as basal, diastolic, maximum, mean arterial, systolic, mean central venous. The present report examines the determinants of systolic blood pressure for two different groups of cardiac patients. One group of cardiac patients is those who underwent dobutamine stress echocardiography, and the other group is Worcester heart attack study. Many systolic blood pressure determinants, their effects, and correlations have been focused in the current report.&amp;lt;/p&amp;gt;</description>
	</item>
	<item>
		<title>The lifestyle modification effectiveness in reducing Hypertension in a Brazilian Community: From the epigenetic basis of Ancestral Survival to the Contemporary Lifestyle and Public Health Initiatives</title>
		<pubDate>05/12/2017</pubDate>
		<link>https://www.theskygallerypattaya.com/hjch/ach-aid1003.php</link>
		<description>&amp;lt;h2&amp;gt;Abstract&amp;lt;/h2&amp;gt;

&amp;lt;p&amp;gt;High blood pressure (HBP) is a strong, independent and etiologically relevant risk factor for cardiovascular and therefore, the leading cause of preventable deaths worldwide. Hypertension has high medical and social costs. Due to its many associated complications, the use of medical services create high costs with medications which represent almost half of the estimated direct expenses. Free distribution of more than 15 medications for HyPERtension and DIAbetes (HIPERDIA program) clearly shows the important role of drugs in the Brazilian Government&amp;amp;rsquo;s effort to tackle these two diseases. Notwithstanding, the prevalence of HBP is rising in parallel with other NCDs. It is known that HBP results from environmental and genetic factors, and interactions among them. Our ancestors were often faced with survival stresses, including famine, water and sodium deprivation. As results of natural selection, the survival pressures drove our evolution to shape a thrifty genotype, which favored/promoted energy-saving and sodium/water preservation. However, with the switch to a sodium- and energy-rich diets and sedentary lifestyle, the thrifty genotype and ancient frugal alleles, are no longer advantageous, and may be maladaptive to disease phenotype, resulting in hypertension, obesity and insulin resistance syndrome. Low-grade chronic inflammation and oxidative stress would be the underlying mechanisms for these diseases. HBP is often associated with unhealthy lifestyles such as consumption of high fat and/or high-salt diets and physical inactivity. Therefore, alternatively to medicine drugs, lifestyle and behavioral modifications are stressed for the prevention, treatment, and control of hypertension. A lifestyle modification program (LSM) involving dietary counseling and regularly supervised physical activity (&amp;amp;ldquo;Move for Health&amp;amp;rdquo;) has been used for decades, in our group, for NCDs primary care. Retrospective (2006-2016) data from 1317 subjects have shown the top quartile of blood pressure(142.2/88.5mmHg) differing from the lower quartile (120.6/69.2mmHg) by being older, with lower schooling, lower income and, lower physical activity and aerobic capacity. Additionally, the P75 showed higher intake of CHO, saturated fat and sodium along with lower-diet quality score with a more processed foods. They showed higher body fatness and prevalence of metabolic syndrome along with higher pro-inflammatory and peroxidative activities and insulin resistance. In this free-demand sample, the HBP rate was 51.2% for SBP and 42.7% for DBP. The rate of undiagnosed HBP was 9.8% and only 1/3 of medicated patients were controlled for HBP. After 10 weeks of LSM the HBP normalization achieved 17.8% for SBP and 9.3% for DBP with a net effectiveness of 8.5% and 2.4%, respectively. The reduction of HBP by LSM was followed by increased aerobic conditioning and reduced intake of processed foods along with decreased values of BMI, abdominal fatness, insulin resistance, pro-inflammatory and peroxydative activities. Importantly, once applied nationwide this LSM would save HBP medication for 3.1 million of hypertensives at an economic saving costs of US$ 1.47 billion a year!&amp;lt;/p&amp;gt;</description>
	</item>
	<item>
		<title>Insights for Antihypertensive pharmacotherapy from theâ€œCalcium Paradoxâ€ due to Ca2+/camp Interaction</title>
		<pubDate>03/27/2017</pubDate>
		<link>https://www.theskygallerypattaya.com/hjch/ach-aid1002.php</link>
		<description>&amp;lt;h2&amp;gt;Abstract&amp;lt;/h2&amp;gt;

&amp;lt;p&amp;gt;Several experimental studies performed since 1975, using smooth muscles richly innervated by sympathetic nerves to exclude the autonomic influence of adjusting reflex (rodent vas deferens), showed that L-type voltage-activated Ca2+ channels (VACC) blockers completely inhibited neurogenic contractions induced by electrical field stimulation (EFS) in high concentrations (&amp;amp;gt;10-6 M), but paradoxically increased these EFS-contractions in low concentrations (&amp;amp;lt;10-6 M), suggesting that other mechanisms than only autonomic adjusting reflex are involved in these paradoxical effects. In 2013, we showed that these paradoxical effects of L-type VACC blockers, named by us &amp;amp;ldquo;calcium paradox&amp;amp;rdquo; phenomenon, were potentiated by drugs which increase cytosolic cAMP concentration ([cAMP] c-enhancers), such as rolipram, IBMX and forskolin, indicating that this sympathetic hyperactivity drug-induced is due to interaction of the Ca2+/cAMP intracellular signaling pathways (Ca2+/cAMP interaction). Then, the pharmacological manipulation of this interaction produced by combination of the L-type VACC blockers used in the antihypertensive therapy, and [cAMP] c-enhancers used in the antidepressive therapy, could represent a potential cardiovascular risk for hypertensive patients due to sympathetic hyperactivity. Then, we discussed the role of Ca2+/cAMP interaction for antihypertensive pharmacotherapy.&amp;lt;/p&amp;gt;</description>
	</item>
	<item>
		<title>Sex Differences in Hypertension: A Question worth Asking?</title>
		<pubDate>01/21/2017</pubDate>
		<link>https://www.theskygallerypattaya.com/hjch/ach-aid1001.php</link>
		<description>&amp;lt;h2&amp;gt;Short Communication&amp;lt;/h2&amp;gt;

&amp;lt;p&amp;gt;Hypertension is a complex disorder involving multiple organ systems and the primarily modifiable risk factor for heart disease, which is the leading cause of death among both men and women in the World. Although both men and women develop hypertension, distinct gender differences in the incidence and severity of hypertension are well established where men have a higher incidence of hypertension compared with women of the same age until the sixth decade of life [1,2]. Despite gender differences in human hypertension, the treatment guidelines do not differ by gender [3]. Even if the causes of hypertension are complex and are related to genetic factors, lifestyle, diet structure, and environmental factors including air pollution [4], coupled with the potential determinants of hypertension, sex differences in hypertension-which exist in human populations-are attributed to both biological and behavioural factors. The biological factors include sex hormones, chromosomal differences, and other biological sex differences that are protective against hypertension in women. These factors become prominent in adolescence and persist through adulthood until women reach menopause. Behavioural risk factors for hypertension include high body mass index, smoking, and low physical activity.&amp;lt;/p&amp;gt;</description>
	</item>
</channel>
</rss>